This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Adhoute, G. Articles by Vasseur, J.J. Search for Related Content PubMed PubMed Citation Articles by Adhoute, G. Articles by Vasseur, J.J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Social Bookmarking                         What's this?

Naftidrofuryl in Chronic Arterial Disease Results of a Six Month Controlled Multicenter Study Using Naftidrofuryl Tablets 200 mg

From the Laboratories Oberval, Lyon, France

F. Bacourt

From the Laboratories Oberval, Lyon, France

M. Barral

From the Laboratories Oberval, Lyon, France

J.M. Cardon

From the Laboratories Oberval, Lyon, France

J.M. Chevalier

From the Laboratories Oberval, Lyon, France

A. Cuny

From the Laboratories Oberval, Lyon, France

M. Gillet

From the Laboratories Oberval, Lyon, France

C. Juhan

From the Laboratories Oberval, Lyon, France

G. Leguay

From the Laboratories Oberval, Lyon, France

J. Marion

From the Laboratories Oberval, Lyon, France

J. Marie

From the Laboratories Oberval, Lyon, France

J. Natali

From the Laboratories Oberval, Lyon, France

H. Nicaise

From the Laboratories Oberval, Lyon, France

P. Plagnol

From the Laboratories Oberval, Lyon, France

P. Revelin

From the Laboratories Oberval, Lyon, France

S. Rouffy

From the Laboratories Oberval, Lyon, France

J.P. Saulnier

From the Laboratories Oberval, Lyon, France

C. Schmidt

From the Laboratories Oberval, Lyon, France

J.J. Vasseur

From the Laboratories Oberval, Lyon, France

The study was carried out on patients with intermittent claudication (Fon taine's stage II). The arterial and atheromatous origin of the disease was con firmed and localized by angiography or Doppler velocimetry examination.

One hundred eighty-six patients were selected initially. Their pain-free walk ing distance on a treadmill (at a speed of 3 km/hour and an inclination of 10%) had to be 150-300 m. During the first month all patients received 3 placebo tablets daily.

At the end of this run-in period (D-30; D 0) and after checking walking distance stability (allowed variation: ±20% between the two measurements) the patients were included in the study. One hundred fifty-four patients were se lected and 118 remained during the whole study. The study was designed as a double-blind, using two parallel randomly selected groups.

Sixty-four patients received for six months Naftidrofuryl (3 x 200 mg tablets daily with meals); 54 patients received placebo under the same conditions. Dur ing this period, clinical and paraclinical examinations were carried out every quarter (D 90 and D 180).

After checking the initial homogeneity of the Naftidrofuryl and placebo- groups, the comparison between groups indicates a significant improvement in Naftidrofuryl group after 3 and 6 months of treatment. At the end of the study the observed differences in walking distance with Naftidrofuryl are approxi mately twice the difference in the reference group (D 90: p < 0.05; D 180: p < 0.02). The results of this study indicate that Naftidrofuryl is an efficient pharmacological tool for treatment of patients with chronic arterial disease (Fontaine's stage II).

Angiology, Vol. 37, No. 3, 160-167 (1986)
DOI: 10.1177/000331978603700304


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?